ABBOTT LABORATORIES Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31)
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) of -$12.07 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecrease · last filed 2012-11-07
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-09-30 was -$12.07M, a 234.31% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $350.00K, a 80.23% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $5.14M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $33.83M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2011 was $19.86M, a 3.45% decline from fiscal 2010.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2010 was $20.57M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-09-30 | -$12.07M 10-Q · filed 2012-11-07 | -$11.72M derived: sum of 2 quarters · filed 2012-11-07 | -$22.37M 10-Q · filed 2012-11-07 | $27.24M derived: sum of 4 quarters · filed 2012-11-07 |
| 2012-06-30 | $350.00K 10-Q · filed 2012-08-07 | -$10.30M 10-Q · filed 2012-08-07 | $39.32M derived: sum of 3 quarters · filed 2012-08-07 | $48.30M derived: sum of 4 quarters · filed 2012-11-07 |
| 2012-03-31 | $5.14M 10-Q · filed 2012-05-08 | $38.97M derived: sum of 2 quarters · filed 2012-05-08 | $47.95M derived: sum of 3 quarters · filed 2012-11-07 | $49.72M derived: sum of 4 quarters · filed 2012-11-07 |
| 2011-12-31 | $33.83M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $42.82M derived: sum of 2 quarters · filed 2012-11-07 | $44.59M derived: sum of 3 quarters · filed 2012-11-07 | $19.86M 10-K · filed 2012-02-21 |
| 2011-09-30 | $8.99M 10-Q · filed 2012-11-07 | $10.76M derived: sum of 2 quarters · filed 2012-11-07 | -$13.97M 10-Q · filed 2012-11-07 | |
| 2011-06-30 | $1.77M 10-Q · filed 2012-08-07 | -$22.96M 10-Q · filed 2012-08-07 | ||
| 2011-03-31 | -$24.75M 10-Q · filed 2012-05-08 | |||
| 2010-12-31 | $20.57M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |